Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forced Technology Transfer Hinders Innovation In China – USTR

This article was originally published in PharmAsia News

Executive Summary

China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.

You may also be interested in...



China To De-link Indigenous Innovation And Public Procurement Policies - U.S.-China Strategic And Economic Dialogue

WASHINGTON - In a positive move for the life sciences industry and others conducting business in China, Chinese leaders have agreed to de-link indigenous innovation policies from government procurement, a decision that - if fully implemented - would provide a fairer competitive environment for foreign-invested enterprises in China

Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report

The failure of U.S. trading partners to adequately protect pharmaceutical test data remains one of the top concerns of the United States Trade Representative in its 2011 Special 301 Report on intellectual property rights

Intellectual Property Protection: Foreign Governments Get To Argue Their Case To USTR Before Publication Of "Watch Lists"

For the first time, the U.S. Trade Representative is giving foreign governments and others a chance to publicly testify before issuing its 2010 Special 301 report on countries it deems do not provide adequate protection of intellectual property rights

Related Content

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel